Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Accounts Payables: 2023-2025

Historic Accounts Payables for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $17.9 million.

  • Monte Rosa Therapeutics' Accounts Payables rose 18.56% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.9 million, marking a year-over-year increase of 18.56%. This contributed to the annual value of $18.8 million for FY2024, which is 28.66% up from last year.
  • Monte Rosa Therapeutics' Accounts Payables amounted to $17.9 million in Q3 2025, which was up 30.04% from $13.8 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Accounts Payables ranged from a high of $18.8 million in Q4 2024 and a low of $10.2 million during Q1 2023.
  • In the last 3 years, Monte Rosa Therapeutics' Accounts Payables had a median value of $14.2 million in 2023 and averaged $14.1 million.
  • Data for Monte Rosa Therapeutics' Accounts Payables shows a peak YoY skyrocketed of 52.03% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Accounts Payables stood at $14.6 million in 2023, then increased by 28.66% to $18.8 million in 2024, then grew by 18.56% to $17.9 million in 2025.
  • Its Accounts Payables stands at $17.9 million for Q3 2025, versus $13.8 million for Q2 2025 and $16.3 million for Q1 2025.